factor

(redirected from hematopoietic growth factor)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia.

Factor

A financial institution that buys a firm's accounts receivable and collects the accounts.

Factor

A third party that buys a firm's accounts receivable. If a firm is not confident in its ability to collect on its credit sales, it may sell the right to receive payment to the factor at a discount. The factor then assumes the credit risk associated with the accounts receivable. This provides the firm immediate access to working capital, which is important, especially if the firm has a cash flow problem. The price of factoring is determined by the creditworthiness of the firm's customer, not of the firm itself. It is also known as accounts receivable financing.

factor

A firm that purchases accounts receivable from another firm at a discount. The purchasing firm then attempts to collect the receivables.

factor

To sell accounts receivable to another party at a discount from face value. Thus, a firm in need of cash to pay down short-term debt may decide to factor its accounts receivable to another firm.

factor

  1. a firm that purchases TRADE DEBTS from client firms. See FACTORING.
  2. a firm that buys in bulk and performs a WHOLESALING function.
  3. an input (for example raw material, labour, capital) which is used to produce a good or provide a service.

factor

  1. 1a FACTOR INPUT that is used in production (see NATURAL RESOURCES, LABOUR, CAPITAL).
  2. a business that buys in bulk and performs a WHOLESALING function.
  3. a business that buys trade debts from client firms (at some agreed price below the nominal value of the debts) and then arranges to recover them for itself. See FACTOR MARKET, FACTORING.
References in periodicals archive ?
Understand both established information and recent clinical advances in immunohematology, bone marrow transplantation, and hematopoietic growth factors
Supportive care consisted of blood and blood product transfusions, prophylactic antibiotics, and hematopoietic growth factors.
In this role, she conducted many breast cancer treatment clinical trials, including evaluation of high-dose chemotherapies and hematopoietic growth factors, new cytotoxic drug combinations, novel hormonal treatments, monoclonal antibody and gene therapies for breast cancer.
DUBLIN, Ireland -- Targeted Therapies Are Forecast to Show the Highest Growth Rate in the Next Four Years, Compared to Chemotherapies, Hormonal Therapies and Hematopoietic Growth Factors - 90% between 2004 and 2008

Full browser ?